Repligen, the bioprocessing company, will issue $1 billion of 0.25% convertible senior notes due 2031. It reached privately negotiated deals with holders of its 1.00% notes due 2028 and with new investors. About $541.4 million of the new notes will be swapped for $456.8 million of the 2028 notes. The other $458.6 million will be sold for cash. The initial conversion price is about $226.37 per share, a 20% premium over the October 29, 2026 closing price. Repligen will use $120 million of the proceeds to buy back shares at $188.64. The rest will go to working capital and general purposes, including possible acquisitions. About $143.2 million of the 2028 notes will remain outstanding. Closing is expected on or about November 6, 2026.

Repligen (NASDAQ:RGEN) shares up 4.5% following better-than-expected earnings. October 28, 2026 Key points. * Repligen beat quarterly expectations: Revenue rose 10.9% year over year to $209.3 million, while adjusted EPS of $0.53 exceeded the $0.46 consensus estimate. Shares rose 4.5% following the results. * Management raised full-year 2026 revenue guidance to $844 million-$852 million and completed its BioLife acquisition, strengthening the company's cell-therapy offerings and growth prospects. * Risks remain despite the upbeat results: a $41.2 million impairment charge weakened GAAP profit, filtration deliveries were pushed into 2027, and the stock's elevated valuation keeps investor expectations high. * Five stocks we like better than Repligen. Repligen Corporation (NASDAQ:RGEN - Get Free Report) was up 4.5% during trading on Wednesday following a better than expected earnings announcement. The stock traded as high as $185.29 and last traded at $183.7640. 163,772 shares changed hands during mid-day trading, a decline of 84% from the average daily volume of 1,049,196 shares. The stock had previously closed at $175.80. The biotechnology company reported $0.53 earnings per share for the quarter, beating analysts' consensus estimates of $0.46 by $0.07. The business had revenue of $209.31 million during the quarter, compared to analysts' expectations of $206.71 million. During the same period last year, the business posted $0.46 earnings per share. The company's revenue for the quarter was up 10.9% compared to the same quarter last year. Key stories impacting Repligen. Here are the key news stories impacting Repligen this week: * Repligen reported third-quarter revenue of $209.3 million, up 10.9% year over year and above the roughly $206.7 million consensus estimate. Adjusted EPS of $0.53 also exceeded expectations of $0.46. * Management raised full-year 2026 revenue guidance to $844 million-$852 million, representing approximately 14.5%-15.5% reported growth. The company also completed its BioLife acquisition, expanding its cell-therapy offerings and potentially accelerating long-term growth. * Some commentary characterized the revenue outlook as a potential catalyst and argued that RGEN could be undervalued if its growth and cash-flow expansion continue. * Valuation remains a key debate. With a very high earnings multiple, one analysis viewed the stock as fairly valued because expected cash-flow growth is already reflected in the share price. * Repligen recorded a $41.2 million impairment charge, causing reported quarterly profit to turn into a loss. Although the charge is noncash, it weakens GAAP results and may prompt investors to focus more heavily on adjusted figures. * The Filtration segment remained weak, and management said some expected system deliveries moved into 2027. That delay creates near-term uncertainty despite strength in Proteins, Chromatography, and Analytics, likely explaining the market's negative reaction to otherwise solid results. Analysts set new price targets. RGEN has been the subject of several research analyst reports. Wells Fargo & Company lifted their target price on Repligen from $180.00 to $185.00 and gave the stock an "overweight" rating in a research report on Thursday, July 30th. Evercore reiterated an "outperform" rating and issued a $160.00 target price on shares of Repligen in a report on Monday, July 6th. Weiss Ratings upgraded Repligen from a "hold (c-)" rating to a "hold (c)" rating in a research note on Thursday, October 8th. Benchmark raised Repligen from a "hold" rating to a "buy" rating and set a $185.00 price target for the company in a report on Tuesday, July 7th. Finally, JPMorgan Chase & Co. boosted their price target on Repligen from $165.00 to $175.00 and gave the stock an "overweight" rating in a research note on Wednesday, July 29th. Two analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $175.71. Institutional inflows and outflows. Several institutional investors have recently made changes to their positions in the business. United Capital Financial Advisors LLC acquired a new stake in shares of Repligen during the 2nd quarter worth approximately $380,756,000. Wasatch Advisors LP raised its holdings in shares of Repligen by 27.9% during the second quarter. Wasatch Advisors LP now owns 1,590,251 shares of the biotechnology company's stock valued at $216,974,000 after acquiring an additional 346,720 shares during the last quarter. Congress Asset Management Co. lifted its position in shares of Repligen by 0.9% in the third quarter. Congress Asset Management Co. now owns 1,020,907 shares of the biotechnology company's stock valued at $196,249,000 after acquiring an additional 8,681 shares in the last quarter. ABS Investment Management LLC acquired a new stake in shares of Repligen in the second quarter worth approximately $191,016,000. Finally, Maverick Capital Ltd. acquired a new stake in shares of Repligen in the first quarter worth approximately $178,946,000. Hedge funds and other institutional investors own 97.64% of the company's stock. Repligen price performance. The stock has a market capitalization of $10.37 billion, a price-to-earnings ratio of 251.19 and a beta of 1.08. The stock has a 50 day moving average price of $177.50 and a 200-day moving average price of $144.99. About Repligen. Repligen Corporation NASDAQ: RGEN develops and manufactures bioprocessing technologies used in the production of biological medicines. Its products support key stages of biopharmaceutical manufacturing, including upstream processing, downstream purification, filtration, process monitoring and fluid management. The company's offerings include chromatography products, filtration systems, single-use technologies, process analytics equipment and critical biological materials such as recombinant proteins. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Repligen, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repligen wasn't on the list. While Repligen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall. Continue following MarketBeat